Scilex Holding announced ZTlido has reached three major milestones since it launched in October 2018. The following three milestones are a testament to the perceived confidence that patients and health care providers have in ZTlido: Over one million patients are estimated to have been treated with ZTlido since its launch according to Symphony Health prescription data. ZTlido is now the number one prescribed non-opioid branded pain medication by pain specialists in the United States, based on Symphony Health prescription data gathered from January 2023 to November 2023. Patients report 89% satisfaction with ZTlido in a 2023 patient survey conducted by Scilex.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCLX:
- Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone – Over One Million Patients Treated Since its Launch – and Two Additional Milestones Met
- Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹
- Scilex announces publication in Anesthesiology Journal of results on ZTlido
- Scilex Holding and B. Riley End $500M Equity Agreement
- Scilex Pharma Resolves Lidocaine Patch Lawsuits Confidently